Skip to main content
Journal cover image

A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma.

Publication ,  Journal Article
Cantrell, LA; Havrilesky, L; Moore, DT; O'Malley, D; Liotta, M; Secord, AA; Nagel, CI; Cohn, DE; Fader, AN; Wallace, AH; Rose, P; Gehrig, PA
Published in: Gynecol Oncol
October 2012

OBJECTIVE: To evaluate the impact of adjuvant post-operative therapy in women with early stage uterine carcinosarcoma. METHODS: After IRB approval was obtained at all sites, a multi-center retrospective study of women with FIGO stage I-II uterine carcinosarcoma diagnosed from 1997 to 2007 was conducted. Post-operative treatment included observation (OBS), radiation (RT), chemotherapy (CT) alone or with RT (CT+RT). Data analyzed included demographic and pathologic factors, adjuvant therapy outcomes, and time-to-event information. The Kaplan-Meier method was used to estimate time-to-event functions. Cox regression modeling was used to examine the impact of selected covariates on progression free survival (PFS), and overall survival (OS). RESULTS: 111 women were identified: 94 (85%) had stage I and 17 (15%) had stage II uterine carcinosarcoma. Forty-four women (40%) did not receive adjuvant therapy (OBS), 29 (26%) women had adjuvant CT, 23 (20%) women underwent RT and 15 (14%) women underwent RT+CT. Seventy-three patients were alive without disease and 38 had progressed or died at the close of data collection. In multivariate analysis, CT (p=0.003), LVSI (p<0.0001) and a pre-existing cancer (p=0.004) were most predictive of PFS. LVSI was predictive of shortened OS (p=0.01). CONCLUSIONS: In women with FIGO stage I-II uterine carcinosarcoma, adjuvant chemotherapy is associated with improved PFS compared to radiation or observation alone. Ongoing clinical trials will clarify the role of chemotherapy in women with this disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

October 2012

Volume

127

Issue

1

Start / End Page

22 / 26

Location

United States

Related Subject Headings

  • Uterine Neoplasms
  • Survival Analysis
  • Risk Factors
  • Retrospective Studies
  • Radiotherapy, Adjuvant
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cantrell, L. A., Havrilesky, L., Moore, D. T., O’Malley, D., Liotta, M., Secord, A. A., … Gehrig, P. A. (2012). A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. Gynecol Oncol, 127(1), 22–26. https://doi.org/10.1016/j.ygyno.2012.06.020
Cantrell, Leigh A., Laura Havrilesky, Dominic T. Moore, David O’Malley, Margaret Liotta, Angeles Alvarez Secord, Christa I. Nagel, et al. “A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma.Gynecol Oncol 127, no. 1 (October 2012): 22–26. https://doi.org/10.1016/j.ygyno.2012.06.020.
Cantrell LA, Havrilesky L, Moore DT, O’Malley D, Liotta M, Secord AA, et al. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. Gynecol Oncol. 2012 Oct;127(1):22–6.
Cantrell, Leigh A., et al. “A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma.Gynecol Oncol, vol. 127, no. 1, Oct. 2012, pp. 22–26. Pubmed, doi:10.1016/j.ygyno.2012.06.020.
Cantrell LA, Havrilesky L, Moore DT, O’Malley D, Liotta M, Secord AA, Nagel CI, Cohn DE, Fader AN, Wallace AH, Rose P, Gehrig PA. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. Gynecol Oncol. 2012 Oct;127(1):22–26.
Journal cover image

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

October 2012

Volume

127

Issue

1

Start / End Page

22 / 26

Location

United States

Related Subject Headings

  • Uterine Neoplasms
  • Survival Analysis
  • Risk Factors
  • Retrospective Studies
  • Radiotherapy, Adjuvant
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Humans
  • Female